The liquid biopsy includes the detection of circulating tumor cells (CTCs) and CTC clusters
in blood, as well as the detection of, cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) …

Liquid biopsy is a promising technique for clinical management of oncological patients. The
diversity of analytes circulating in the blood useable for liquid biopsy testing is enormous …

Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …

Precision medicine was born with the development of new diagnostic techniques and
targeted drugs, yielding better outcomes in cancer care. With the evolution and increasing …

Circulating tumor cells (CTCs) are a rare subset of cells found in the blood of patients with
solid tumors, which function as a seed for metastases. Cancer cells metastasize through the …

Cancer is a highly heterogeneous disease that is frequently diagnosed at an advanced
stage with the presence of metastatic disease resulting in limited treatment options and a …

Technological advancements in research on circulating biomarkers from patient derived
blood have enabled a less invasive means of diagnosing non-hematologic cancers …

The emergence of immunotherapy in oncology requires the discovery, validation and
subsequent adoption of robust, sensitive and specific predictive and prognostic biomarkers …

Liquid biopsies have been receiving tremendous attentions as easy, rapid, and non-invasive
tools for cancer diagnosis. Liquid biopsy can be performed repeatedly for disease …

Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body
fluids, is increasingly used in cancer management. An overview of relevant literature …